News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
BioMarin Pharmaceutical's (BMRN) Alesta acquisition adds a new pipeline opportunity and supports long-term growth, Wedbush Securities said in a note Tuesday. The company said earlier Tuesday that it is acquiring Alesta Therapeutics for as much as $490 million with the goal of Silver Upgrade …
Sharemaestro market context New activity signal 52 weeks +11.9% · Next-week setup negative 4.6%Earnings Call Insights: NRx Pharmaceuticals (NRXP) Q2 2026 MANAGEMENT VIEW * “The second quarter of 2026, was a major inflection point for our company across multiple key objectives” (Co-Founder, Chairman & CEO Jonathan Javitt), citing progress on preservative-free ketamine, regulatory path for NRX-100, a …
EDMOND, Okla., Aug. 18, 2026 /PRNewswire/ -- Pinnacle Technology Solutions (PTS) and Pinnacle Business Systems (PBS) announce that Rob Anderson will retire from his role as Chief Executive Officer of Pinnacle Business Systems following 27 years of leadership with the company. David Traxler has …
EyePoint EYPT announced top-line results from the first of two pivotal late-stage clinical studies evaluating its investigational candidate, Duravyu (vorolanib intravitreal insert), in patients with wet age-related macular degeneration (wet AMD). The study did not meet its primary endpoint of non-inferiority on change from …
Sharemaestro market context Trend signal active 52 weeks +87.3% · Next-week setup positive 58.0%Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. MACOM Technology Solutions Holdings (MTSI) moved back into focus after fresh earnings and guidance on 6 August 2026, along with a 3% share …
The Gross Law Firm has issued a shareholder alert for investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who suffered losses during the class period of August 1, 2025, to May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its …
This M&A roundup details several significant deals in the pharmaceutical sector, including LEO Pharma's acquisition of dersimelagon for rare skin diseases, BioMarin's purchase
Santhera nears cash break-even as AGAMREE gains traction, Edison says Proactive uses images sourced from Shutterstock Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss rare-disease drugmaker, is closing in on a financial turning point, according to research house Edison. In a QuickView note published on …
Regeneron has discontinued a Phase 1/2 study for REGN7041, an investigational anti-inflammatory antibody for non-infectious uveitis, due to an unfavorable benefit-risk assessment following an unspecified safety event. This setback adds to a series of recent clinical trial failures for Regeneron, increasing pressure from analysts …
Takeda Pharmaceutical Co. (TAK) closed the last trading session at $17.38, gaining 1.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price …
Amylyx Pharmaceuticals (NASDAQ:AMLX) reached a new 52-week high after Mizuho raised its price target from $24 to $30 and maintained an outperform rating. The stock traded as high as $28.95 and closed at $29.8120, with a consensus "Moderate Buy" rating from analysts. Despite missing …
Amylyx Pharmaceuticals announced positive topline results from its Phase 3 LUCIDITY clinical trial of avexitide for post-bariatric hypoglycemia (PBH). The trial met its primary endpoint, showing a 55% reduction in hypoglycemic events, and all secondary endpoints. Amylyx plans to submit a New Drug Application …
BioMarin Pharmaceutical has acquired Alesta Therapeutics for an upfront payment of $275 million, with an additional $215 million in potential milestones. This acquisition aims to position BioMarin to compete with AstraZeneca in the rare bone disease market, specifically hypophosphatasia (HPP), with Alesta's oral drug …
Bernstein Liebhard LLP has announced a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements, leading to …
Macy's is launching a 100-day countdown to its 100th Thanksgiving Day Parade, inviting customers to celebrate this centennial milestone. The parade will feature a record-breaking 100 inflatable elements, including new characters and the return of favorites like Underdog and Felix the Cat, alongside a …
Sharemaestro market context Trend signal active 52 weeks +72.6% · Next-week setup negative 39.1%Banco Macro S.A. (BMA) is showing surging implied volatility, particularly for its Oct. 16, 2026 $35.00 Put option, indicating market expectation of significant price movement. Analysts currently rate Banco Macro as a Zacks Rank #2 (Buy) with rising earnings estimates, suggesting this high volatility …
Sharemaestro market context Trend signal active 52 weeks +47.8%BioMarin Pharmaceutical Inc. announced its acquisition of Alesta Therapeutics for $275 million upfront, causing BioMarin's shares to rise by 4.7% in premarket trading. The deal grants BioMarin access to ALE1, an oral therapy for hypophosphatasia (HPP) currently in clinical trials, with potential additional payments …
Royal Bank of Canada reiterated its "sector perform" rating for EyePoint Pharmaceuticals (EYPT) but significantly cut its price target to $5 from $37, citing uncertainty after the DURAVYU Phase 3 LUGANO trial missed its primary endpoint. Despite this, other analysts remain divided, with some …
Rocket Pharmaceuticals CEO Gaurav Shah sold 2,837 shares of company stock worth $9,591 to cover tax obligations from vested Restricted Stock Units. Despite this sale, Shah retains significant holdings. The company also recently sold a Rare Pediatric Disease Priority Review Voucher for $180 million …
BTIG Research has reaffirmed a "Buy" rating for NRx Pharmaceuticals (NASDAQ:NRXP) and set a $10 price target, suggesting a potential upside of 191.55% from its current price of $3.43. This comes despite NRx Pharmaceuticals reporting a quarterly loss of $0.44 per share and revenue …
BioMarin to pay $275 million upfront, plus additional payments upon achievement of development and regulatory milestones Alesta to spin out all non-ALE1 assets to a new entity and Alesta employees to transfer to the spinout entity prior to close ALE1 has significant potential to …
Sharemaestro market context New activity signal 52 weeks +11.9% · Next-week setup negative 4.6%Crinetics Pharmaceuticals (CRNX) has shown strong returns over the past three years, but its current valuation, particularly its P/B ratio of 7.5x compared to an industry average of 2.5x, suggests it is overvalued. Despite a mixed overall valuation profile, the market appears to be …
Amylyx Pharmaceuticals (AMLX) announced positive results from its Phase 3 LUCIDITY trial for avexitide, a GLP-1 receptor antagonist. The drug successfully met its main goals in patients experiencing low blood sugar after gastric bypass surgery. This news led to a surge in Amylyx's stock.
Humacyte (Nasdaq: HUMA) announced that board-certified vascular surgeon Jeromy Brink, MD, performed the first four post-BLA-approval Symvess implants in Arizona within two weeks. Symvess is an FDA-approved off-the-shelf bioengineered blood vessel for urgent revascularization in extremity arterial injury when autologous vein grafts are not …
HC Wainwright analysts have increased their Q3 2026 earnings per share estimate for Rigel Pharmaceuticals (NASDAQ:RIGL) to $0.99 from $0.68, maintaining a "Buy" rating and an $85 price target. This revision follows Rigel's strong quarterly results, where EPS of $0.88 significantly beat the $0.09 …
Milestone Pharmaceuticals (MIST) is reiterated as a 'Sell' due to the weak differentiation of its product, CARDAMYST, and its poor commercial uptake compared to low-cost generics. The company's financial health is deteriorating with low revenue, heavy discounting, minimal payer coverage, and increasing liabilities. Despite …
Regeneron has terminated a Phase 1/2 study of its investigational anti-inflammatory antibody, REGN7041, for non-infectious uveitis due to an "unfavorable benefit-risk assessment." This marks another clinical setback for Regeneron, following failures of itepekimab for COPD and a melanoma combo. Despite these challenges, the company, …
Rhythm Pharmaceuticals (RYTM) has seen a significant 5-year return, but its current valuation, particularly its high P/S ratio of 33.1x, suggests it may be overvalued compared to the biotech industry average and its own tailored fair P/S ratio of 19.7x. While recent positive news …
Proceeds to support a potentially registrational clinical study in less severe inclusion body myositis (IBM) patients expected to begin in Q4 2026 and report top line results in 2H 2028 Ulviprubart showed a trend toward clinically meaningful slowing of disease progression in patients with …
Search by ticker symbol or company name and select a result to open its chart. The US only control limits results to active US-listed stocks and ETFs.
Showing active US-listed stocks and ETFs only.